Cargando...
Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
The incorporation of novel agents such as bortezomib and lenalidomide into initial therapy for multiple myeloma has improved the response rate of induction regimens. Also, these drugs are being increasingly used in the peri-transplant setting for transplant-eligible patients, and as part of consolid...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2013
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3819933/ https://ncbi.nlm.nih.gov/pubmed/24135408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminoncol.2013.07.007 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|